Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06956157
PHASE4

NAC for Treatment-Resistant OCD and Other Related Disorders

Sponsor: Guangdong Provincial People's Hospital

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind, placebo-controlled study investigating N-acetylcysteine (NAC) as an augmentation therapy for individuals with treatment-resistant obsessive-compulsive disorder (TR-OCD), studied within a broader cohort of treatment-resistant Obsessive-Compulsive and Related Disorders (OCRDs). The study's primary aim is to investigate the neurobiological mechanism by which NAC improves inhibitory control deficits in TR-OCD. This is achieved by using Magnetic Resonance Spectroscopy (MRS) to measure changes in thalamic glutamatergic metabolism. A secondary aim is to assess the clinical efficacy of this augmentation strategy on symptom severity. The central hypothesis is that improvements in inhibitory control are mediated by NAC-induced changes in brain glutamate levels.

Official title: Altered Brain Glutamate Level and Inhibitory Control in Treatment-Resistant Obsessive-Compulsive Disorder After N-acetylcysteine (NAC) Augmentation Therapy

Key Details

Gender

All

Age Range

12 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2022-06-22

Completion Date

2025-11-13

Last Updated

2025-09-03

Healthy Volunteers

Yes

Interventions

DRUG

N-Acetylcysteine Tablets

In addition to participants' existing medication regimens, NAC will be added.

DRUG

Placebo Oral Tablet

Placebo oral tablets are identical in appearance (size, shape, color), packaging, taste, and administration schedule to the N-Acetylcysteine tablets to maintain blinding. The tablets contain inert excipients and no active pharmacological ingredients.

Locations (1)

Guangdong Mental Health Center, Guangdong Provincial People's Hospital

GuangDong, Guangdong, China